Epcoritamab: Clinical Trial Results for DLBCL Treatment
- Here's a summary of the outcomes for patients with newly diagnosed DLBCL, specifically focusing on those considered high-risk or frail/older, based on the provided text:
- * The EPCORE NHL‑2 trial focused on adults with newly diagnosed CD20-positive DLBCL who were ineligible for full-dose R‑CHOP chemotherapy due to: * Age 75 years...
- * Patients received a fixed-duration regimen of epcoritamab (a subcutaneous antibody) combined with R‑mini‑CHOP (a reduced dose of the standard chemotherapy).
Outcomes for Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) – Focus on High-Risk & Frail/Older Populations
Here’s a summary of the outcomes for patients with newly diagnosed DLBCL, specifically focusing on those considered high-risk or frail/older, based on the provided text:
Study & Population:
* The EPCORE NHL‑2 trial focused on adults with newly diagnosed CD20-positive DLBCL who were ineligible for full-dose R‑CHOP chemotherapy due to:
* Age 75 years or older
* Age 65 years or older with significant comorbidities.
* Median age of patients in the study was 81 years (range 74-90).
Treatment Regimen:
* Patients received a fixed-duration regimen of epcoritamab (a subcutaneous antibody) combined with R‑mini‑CHOP (a reduced dose of the standard chemotherapy).
* Epcoritamab was given weekly for the first two cycles, then every three weeks for cycles 3-6, and every four weeks for cycles 7-8, with a step-up dosing schedule.
Key Outcomes:
* High Response Rates:
* Overall Response Rate (ORR): 89%
* Complete Response Rate (CR): 86%
* Durable Responses:
* Median duration of response and complete response were not reached (meaning responses are lasting a long time).
* Excellent Survival:
* Estimated 2-year progression-Free Survival (PFS): 76%
* Estimated 2-year Overall Survival (OS): 82%
* High MRD Negativity:
* 95% of evaluable patients achieved minimal residual disease (MRD) negativity (meaning very few or no cancer cells remained after treatment).This was observed even in patients with:
* High IPI scores (3-5, indicating higher risk) – 93% achieved MRD negativity
* Bulky disease – 89% achieved MRD negativity
* 86% of patients who were MRD-negative at cycle 3 day 1 (C3D1) remained MRD-negative through cycle 6 day 1 (C6D1).
* Treatment Completion & Dose Intensity:
* 79% of patients completed treatment.
* Median R-mini-CHOP dose intensity was high, at 94% or greater.
Safety:
* Grade 3 or greater infections occurred in 29% of patients.
* 11% of patients discontinued epcoritamab due to treatment-emergent adverse events.
In summary: The combination of epcoritamab and R-mini-CHOP appears to be a promising treatment option for newly diagnosed DLBCL in patients who are ineligible for standard, full-dose R-CHOP due to age or comorbidities. It demonstrates high response rates, durable responses, excellent survival, and high rates of MRD negativity, even in high-risk subgroups. While there are safety concerns (particularly infections), the overall results suggest a significant benefit for this challenging patient population.